Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling

Linjie Zhao; Chuan Yu; Shengtao Zhou; Wayne Bond Lau; Bonnie Lau; Zhongyue Luo; Qiao Lin; Huiliang Yang; Yu Xuan; Tao Yi; Xia Zhao; Yuquan Wei

doi:10.18632/oncotarget.6368

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling

Linjie Zhao, Chuan Yu, Shengtao Zhou _, Wayne Bond Lau, Bonnie Lau, Zhongyue Luo, Qiao Lin, Huiliang Yang, Yu Xuan, Tao Yi, Xia Zhao and Yuquan Wei

PDF | HTML | How to cite

Oncotarget. 2016; 7:1408-1420. https://doi.org/10.18632/oncotarget.6368

Metrics: PDF 3193 views | HTML 2655 views | ?

Abstract

Linjie Zhao1,2*, Chuan Yu1,2*, Shengtao Zhou1,2*, Wayne Bond Lau3, Bonnie Lau4, Zhongyue Luo5, Qiao Lin5, Huiliang Yang6, Yu Xuan1,2, Tao Yi1,2, Xia Zhao1,2 and Yuquan Wei1,2

1 Department of Gynecology and Obstetrics, Key Laboratory of Obstetrics & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Chengdu, China

2 The State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

3 Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

4 Department of Surgery, Emergency Medicine, Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA, USA

5 College of Biological Sciences, Sichuan University, Chengdu, China

6 Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, China

* These authors have contributed equally to this work

Correspondence to:

Shengtao Zhou, email:

keywords: ovarian cancer, PDLIM2, DNA methylation, NOS2, nitric oxide signaling

Received: July 04, 2015 Accepted: November 15, 2015 Published: November 22, 2015

Abstract

Ovarian cancer constitutes one of the most lethal gynaecological malignancies worldwide and currently no satisfactory therapeutic approaches have been established. Therefore, elucidation of molecular mechanisms to develop targeted therapy of ovarian cancer is crucial. PDLIM2 is critical to promote ubiquitination of nuclear p65 and thus its role in inflammation has been highlighted recently. We demonstrate that PDLIM2 is decreased in both ovarian high-grade serous carcinoma and in various human ovarian cancer cell lines compared with normal ovary tissues and human ovarian surface epithelial cells (HOSE). Further functional analysis revealed that PDLIM2 is epigenetically repressed in ovarian cancer development and inhibition of PDLIM2 promoted ovarian cancer growth both in vivo and in vitro via NOS2-derived nitric oxide signaling, leading to recruitment of M2 type macrophages. These results suggest that PDLIM2 might be involved in ovarian cancer pathogenesis, which could serve as a promising therapeutic target for ovarian cancer patients.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6368

Publication Alerts

Research Papers:

Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling

Abstract